An agent for enhancing skin barrier function was provided with.

An agent for enhancing skin barrier function comprising a wavelength conversion substance as an active ingredient; a composition and a product comprising the agent for enhancing skin barrier function; and a method for enhancing skin barrier function using thereof. The present invention can exhibit a desirable effect on skin by effectively making use of ultraviolet light to enhance skin barrier function.

Disclosed are a polysaccharide-peptide composite and a method of preparing the same. The polysaccharide-peptide composite is prepared from a bitter melon peptide (BMP) powder, gardenia fruit oil, a soybean polypeptide powder, an oat dietary fiber powder, a konjac powder, a corn silk, a mulberry leaf extract, a Poria cocos extract, a hawthorn extract, nutritional yeast and a pancreatin. The BMP powder is prepared by temperature-controlled hydrolysis, staged enzymatic hydrolysis and multiple filtrations. The gardenia fruit oil is prepared by staged enzymatic hydrolysis, multi-step centrifugation, filtration and stratification.

Disclosed are a polysaccharide-peptide composite and a method of preparing the same. The polysaccharide-peptide composite is prepared from a bitter melon peptide (BMP) powder, gardenia fruit oil, a soybean polypeptide powder, an oat dietary fiber powder, a konjac powder, a corn silk, a mulberry leaf extract, a Poria cocos extract, a hawthorn extract, nutritional yeast and a pancreatin. The BMP powder is prepared by temperature-controlled hydrolysis, staged enzymatic hydrolysis and multiple filtrations. The gardenia fruit oil is prepared by staged enzymatic hydrolysis, multi-step centrifugation, filtration and stratification.

Liquid dressing compositions liquid for use in the treatment or prevention of infection and/or wounds are described that comprise shellac, an anti-infective metal active and a solvent. The compositions are capable of forming a barrier when topically applied to a subject, providing an easily applied barrier for protecting lesions and other wounds from external infective agents.

Liquid dressing compositions liquid for use in the treatment or prevention of infection and/or wounds are described that comprise shellac, an anti-infective metal active and a solvent. The compositions are capable of forming a barrier when topically applied to a subject, providing an easily applied barrier for protecting lesions and other wounds from external infective agents.

Provided are dietary supplement composition comprising one or both of L-theanine and a trace mineral complex, optionally in combination with bioactive peptides, in an amount or amounts individually or in combination effective to promote gut health. Further optional components include a fiber oligosaccharide prebiotic, a polyphenol prebiotic, and a polynucleotide or blend. Examples of benefits include one or more of: —an increase in the amount of total short-chain fatty acid production or of at least one of propionate, acetate and butyrate; —an increase the expression or level of at least one tight junction protein (for example, claudin-1, claudin-3, claudin-4, occludin, or a zona occludens protein) or mucin-3 or decrease the expression or level of claudin-2; —an increase in transepithelial electrical resistance; —an increase in the abundance or diversity of a member or phylum of the intestinal bacterial community of the Intestinal lumen or mucus area (for example, Firmicutes, Bacteroidetes, Lactobacilli, Bifidobacteria, F. prausnitzii, or A. muciniphila); —an increase in the expression or level of at least one intestinal surface area marker protein (for example, villin, myosin, cadherin or sucrase-isomaltase). Methods for using such supplements are also disclosed.

Provided are dietary supplement composition comprising one or both of L-theanine and a trace mineral complex, optionally in combination with bioactive peptides, in an amount or amounts individually or in combination effective to promote gut health. Further optional components include a fiber oligosaccharide prebiotic, a polyphenol prebiotic, and a polynucleotide or blend. Examples of benefits include one or more of: —an increase in the amount of total short-chain fatty acid production or of at least one of propionate, acetate and butyrate; —an increase the expression or level of at least one tight junction protein (for example, claudin-1, claudin-3, claudin-4, occludin, or a zona occludens protein) or mucin-3 or decrease the expression or level of claudin-2; —an increase in transepithelial electrical resistance; —an increase in the abundance or diversity of a member or phylum of the intestinal bacterial community of the Intestinal lumen or mucus area (for example, Firmicutes, Bacteroidetes, Lactobacilli, Bifidobacteria, F. prausnitzii, or A. muciniphila); —an increase in the expression or level of at least one intestinal surface area marker protein (for example, villin, myosin, cadherin or sucrase-isomaltase). Methods for using such supplements are also disclosed.

The present invention relates to a method for increasing the blood-brain barrier permeability, and more particularly, to a method for increasing the blood-brain barrier permeability, the method including: (S1) a step of delivering a nanogenerator carrying a nitric oxide (NO) donor to a site adjacent to the blood-brain barrier; (S2) a step of delivering a first triggering stimulus to an area where the nanogenerator has been delivered so as to release nitric oxide from the nanogenerator; and (S3) a step of allowing the released nitric oxide to activate matrix metallopeptidase-9 (MMP-9) and inducing the activated MMP-9 to weaken the tight junction between a cerebrovascular endothelial cell and another cerebrovascular endothelial cell.

The present invention relates to a method for increasing the blood-brain barrier permeability, and more particularly, to a method for increasing the blood-brain barrier permeability, the method including: (S1) a step of delivering a nanogenerator carrying a nitric oxide (NO) donor to a site adjacent to the blood-brain barrier; (S2) a step of delivering a first triggering stimulus to an area where the nanogenerator has been delivered so as to release nitric oxide from the nanogenerator; and (S3) a step of allowing the released nitric oxide to activate matrix metallopeptidase-9 (MMP-9) and inducing the activated MMP-9 to weaken the tight junction between a cerebrovascular endothelial cell and another cerebrovascular endothelial cell.

Described herein are compositions and methods for treating constipation in an individual. In some embodiments, the composition and method for treating constipation comprises providing an individual with a therapeutic that comprises a food item and a laxative.